Pyrosequencing method for genotyping cytochrome P450CYP2C8 and CYP2C9 enzymes

被引：27

作者：

Hruska, MW ^{[1
]}

Frye, RF ^{[1
]}

Langaee, TY ^{[1
]}

机构：

[1] Univ Florida, Coll Pharm, Gainesville, FL 32610 USA

来源：

CLINICAL CHEMISTRY | 2004年 / 50卷 / 12期

关键词：

D O I：

10.1373/clinchem.2004.040071

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：2392 / 2395

页数：4

共 18 条

[1] Comparison of cytochrome P4502C9 genotyping methods and implications for the clinical laboratory [J].

Aquilante, CL ;

Lobmeyer, MT ;

Langaee, TY ;

Johnson, JA .

PHARMACOTHERAPY, 2004, 24 (06) :720-726

[2] CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes [J].

Bahadur, N ;

Leathart, JBS ;

Mutch, E ;

Steimel-Crespi, D ;

Dunn, SA ;

Gilissen, R ;

Van Houdt, J ;

Hendrickx, J ;

Mannens, G ;

Bohets, H ;

Williams, FM ;

Armstrong, M ;

Crespi, CL ;

Daly, AK .

BIOCHEMICAL PHARMACOLOGY, 2002, 64 (11) :1579-1589

[3] Discovery of new potentially defective alleles of human CYP2C9 [J].

Blaisdell, J ;

Jorge-Nebert, LF ;

Coulter, S ;

Ferguson, SS ;

Lee, SJ ;

Chanas, B ;

Xi, T ;

Mohrenweiser, H ;

Ghanayem, B ;

Goldstein, JA .

PHARMACOGENETICS, 2004, 14 (08) :527-537

[4] Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population [J].

Burian, M ;

Grösch, S ;

Tegeder, I ;

Geisslinger, G .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :518-521

[5] The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].

Crespi, CL ;

Miller, VP .

PHARMACOGENETICS, 1997, 7 (03) :203-210

[6] Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid [J].

Dai, D ;

Zeldin, DC ;

Blaisdell, JA ;

Chanas, B ;

Coulter, SJ ;

Ghanayem, BI ;

Goldstein, JA .

PHARMACOGENETICS, 2001, 11 (07) :597-607

[7] Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].

Dickmann, LJ ;

Rettie, AE ;

Kneller, MB ;

Kim, RB ;

Wood, AJJ ;

Stein, CM ;

Wilkinson, GR ;

Schwarz, UI .

MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387

[8] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].

Goldstein, JA .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355

[9] Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:: genetic analysis of the CYP2C9 locus [J].

Imai, J ;

Ieiri, I ;

Mamiya, K ;

Miyahara, S ;

Furuumi, H ;

Nanba, E ;

Yamane, M ;

Fukumaki, Y ;

Ninomiya, H ;

Tashiro, N ;

Otsubo, K ;

Higuchi, S .

PHARMACOGENETICS, 2000, 10 (01) :85-89

[10] Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin [J].

Kidd, RS ;

Curry, TB ;

Gallagher, S ;

Edeki, T ;

Blaisdell, J ;

Goldstein, JA .

PHARMACOGENETICS, 2001, 11 (09) :803-808

← 1 2 →